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Calibrating from Within: Multipoint Internal
Calibration of a Quantitative Mass Spectrometric
Assay of Serum Methotrexate
Melissa A. Hoffman,a Michael Schmeling,b Jayme L. Dahlin,c Nicholas J. Bevins,a Donald P. Cooper,d
Petr Jarolim,c Robert L. Fitzgerald,a and Andrew N. Hoofnagleb,*
BACKGROUND: Clinical LC-MS/MS assays traditionally
require that samples be run in batches with calibration
curves in each batch. This approach is inefficient and
presents a barrier to random access analysis. We devel-
oped an alternative approach called multipoint internal
calibration (MPIC) that eliminated the need for batch-
mode analysis.
METHODS: The new approach used 4 variants of
13C-labeled methotrexate (0.026–10.3mM) as an internal
calibration curve within each sample. One site carried out a
comprehensive validation, which included an evaluation
of interferences and matrix effects, lower limit of
quantification (LLOQ), and 20-day precision. Three sites
evaluated assay precision and linearity. MPIC was also com-
pared with traditional LC-MS/MS and an immunoassay.
RESULTS: Recovery of spiked analyte was 93%–102%.
The LLOQ was validated to be 0.017 mM. Total vari-
ability, determined in a 20-day experiment, was
11.5%CV. In a 5-day variability study performed at
each site, total imprecision was 3.4 to 16.8%CV.
Linearity was validated throughout the calibrator range
(r2 > 0.995, slopes ¼ 0.996–1.01). In comparing 40
samples run in each laboratory, the median interlabora-
tory imprecision was 6.55%CV. MPIC quantification
was comparable to both traditional LC-MS/MS and im-
munoassay (r2 ¼ 0.96–0.98, slopes ¼ 1.04–1.06).
Bland-Altman analysis of all comparisons showed biases
rarely exceeding 20% when MTX concentrations were
>0.4 mM.
CONCLUSION: The MPIC method for serum methotrexate
quantification was validated in a multisite proof-of-concept
study and represents a big step toward random-access LC-
MS/MS analysis, which could change the paradigm of mass
spectrometry in the clinical laboratory.
Introduction
The conventional workflow for LC-MS/MS clinical
assays includes a calibration curve with each batch of
samples, leading to a substantial increase in the cost per
batch (1). Performing batch-mode analyses also
increases turnaround time (TAT) and makes STAT
sample analysis challenging. The utility of including a
full calibration curve in each batch has been questioned
(2); however, most clinical laboratories continue to op-
erate in this fashion. Batch testing is also less than ideal
in personalized medicine strategies, including therapeu-
tic drug monitoring, where rapid reporting of serum
concentrations is essential for optimizing dosage. To im-
prove laboratory efficiency and to make therapeutic
drug-monitoring analysis by LC-MS/MS more accessi-
ble, alternative calibration strategies have been used, in-
cluding reduction in the number of calibrators and
internal calibration (1, 3, 4). Others have explored re-
sponse factor–based calibration schemes or single-point
calibration to eliminate the need to run a calibration
curve with every sample batch (5, 6). Our goal was to
develop a new calibration strategy using multipoint in-
ternal calibration (MPIC) in a modified isotope-dilution
approach in which every sample contained its own
matrix-matched calibration curve. The proof-of-concept
was demonstrated using the quantification of metho-
trexate (MTX) in serum.
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We selected MTX as the model because high-dose
MTX therapy requires therapeutic monitoring to miti-
gate nephrotoxicity by administering leucovorin or
glucarpidase when supratherapeutic MTX serum con-
centrations are observed (7). MTX’s narrow therapeutic
window and highly variable intrapatient drug absorption
and metabolism also necessitate frequent monitoring
until plasma concentrations below 0.05 to 0.1 mM are
achieved (7, 8).
Immunoassays for MTX are subject to interference
with different compounds and metabolites (e.g., deoxya-
minopteroic acid) depending on which assay is used
(8–11). Coadministration of MTX with glucarpidase
rapidly converts MTX to deoxyaminopteroic acid (12),
which can lead to assay interference for days following
treatment (13). LC-MS/MS has been used by some clin-
ical laboratories to overcome interference issues with
MTX immunoassays (9, 14, 15). Although LC-MS/MS
is a powerful tool resulting in analytically sensitive and
specific measurements, reliance on external calibration
curves and sample batching makes it difficult for clinical
laboratories to provide the rapid TATs that are required
for optimal rescue therapy.
The MPIC method described includes multiple
isotope-labeled MTX internal standards, each at a differ-
ent concentration, as calibrators in each sample; this
approach eliminates the need to batch samples and
reduces the costs of external calibrator preparation and
analysis. We describe the multisite assay validation of
MPIC analysis of MTX in serum.
Materials and Methods
CHEMICALS AND REAGENTS
MTX-certified reference material and powdered pure
MTX were purchased from Cerilliant (M-136) and
EMD Millipore, respectively. Defibrinated plasma
(UTAK) was used for spiking experiments. MPIC in-
ternal calibrators were custom synthesized by
Cerilliant to specifications developed by Waters Corp
(see Supplemental Fig. 1 in the online Data
Supplement). Detailed summaries of calibrator purity
assessment and value assignment are described in the
Supplemental Methods section of the online Data
Supplement (see Supplemental Figs. 2 and 3 and
Supplemental Tables 1 and 2). MPIC microcentrifuge
tubes containing four 13C-labeled MTX analogs (iso-
topologues; 0.026–10.3 mM) were prepared centrally
and sent to each of the 3 sites on dry ice. They were
stored locally at 20C until used. LC-MS/MS–grade
solvents, ammonium acetate, and formic acid were
purchased from Fisher Scientific, and water was either
LC-MS/MS grade or 18.2 mX purified water (Purelab
Ultra).
PATIENT SERUM SAMPLES
All samples used for these studies were leftover, deiden-
tified, and uncoded samples from the clinical laborato-
ries (exempt from institutional review board approval).
Site 1 prepared high- and low-spiked samples for preci-
sion and linearity experiments by dissolving pure MTX
into defibrinated plasma. At Site 2, high- and low-con-
centration serum pools were prepared using excess sera
from patients treated with MTX that had been ana-
lyzed by immunoassay (ARKTM; ARK Diagnostics).
These samples had been refrigerated for up to 5 days
and were then frozen at 20C until analysis. To
make a high pool, patient samples with high concen-
trations (i.e., >10 mM) were combined and then di-
luted with MTX-negative serum (verified by
immunoassay) to approximately 4 mM. Samples with
0.05 mM MTX were combined to form the low-pool
sample. These 2 pools were used for the precision and
linearity experiments.
Samples for the method comparison study were
prepared at Site 1. Forty samples were distributed to
Sites 2 and 3; of those, 17 were from single individuals.
The other 23 samples were blends made using 10 sam-
ples with high amounts of MTX (>10 mM) mixed with
23 different leftover deidentified clinical samples that
had undetectable concentrations of MTX to cover the
clinically relevant range.
MPIC SAMPLE PREPARATION
Samples were prepared at room temperature by adding
50 mL of serum directly to the MPIC vials containing
the dried MTX internal calibrators, then vortexed for
30 s on a multitube vortex mixer. Next, proteins were
precipitated with 250 mL methanol and then vortexed
on a multitube vortex mixer for another 30 s. Samples
were centrifuged at 16 100g for 2min. The supernatant
was transferred to a 96-well plate or Eppendorf tube and
either analyzed directly (Site 1, 20 mL injection volume)
or diluted (Sites 2 and 3, 50 mL supernatant plus
950 mL water for a final concentration of 5% vol:vol
methanol, 10 mL injection volume).
LC-MS/MS
Three different LC-MS/MS platforms were used:
ACQUITY-Xevo TQD, ACQUITY-Xevo TQ-S micro,
and Alliance 2795-Quattro micro. All HPLCs used
2mM ammonium acetate and 0.1% formic acid (v/v) in
water as mobile phase A and methanol with the same
modifiers as mobile phase B (MPB). At Site 1, separa-
tion was achieved using an Ascentis Express C18 col-
umn (2.1mm i.d.  20mm, 2.7-lm particles) and a
0.6-min gradient (10%–100% MPB). Sites 2 and 3
used an ACQUITY UPLC HSS C18 SB column
(2.1mm i.d.  30mm, 1.8-mm particles; Waters Corp)
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with isocratic elution (23% MPB) followed by a 0.5-
min regeneration gradient (23%–95% MPB). The
multiple-reaction monitoring parameters used for MTX
analysis, including transitions and dwell times, are
shown in Supplemental Table 3. Longer dwell times
were used at lower concentrations to improve signal-to-
noise. The cone voltage was 30 and 36V, and the colli-
sion energy was 20 and 18 eV at Site 1 and Sites 2 and
3, respectively. Example chromatograms from the differ-
ent chromatographic methods are provided (Fig. 1, A,
and Supplemental Fig. 4).
RECOVERY AND INTERFERENCES
Certified reference MTX was spiked into defibrinated
plasma at a concentration of 11.92 mM. This sample
was then gravimetrically added to 3 samples. One sam-
ple was defibrinated plasma with no detectable MTX;
the other 2 were patient samples that contained MTX.
The samples were each analyzed as 3 technical replicates.
Recovery was calculated based on the expected D for
each sample.
To evaluate the impact of interferences on MPIC
quantification, samples with high concentrations of hemo-
globin (>0.9 g/dL, n¼ 2), high triglycerides (>600mg/
dL, n¼ 2), and high total protein (>9 g/dL, n¼ 3) were
spiked as described, and MTX was measured.
MATRIX EFFECTS
Extraction efficiency and ion suppression were evaluated
based on the recovery of multipoint internal calibrators
(16). The internal calibrators in MPIC tubes were
reconstituted in 3 different ways: (a) 300 mL solvent was
added and incubated at room temperature and vortexted
for 30 s; (b) leftover clinical samples were extracted in a
separate microcentrifuge tube as normal, and the super-
natant was transferred to an MPIC tube; and (c) the
same leftover clinical samples were extracted in an
MPIC tube as normal. The slope of the calibration
curve in each sample was determined, and extraction ef-
ficiency was calculated as the ratio of slope C to slope B,
expressed as a percentage. Ion suppression was then cal-
culated as 1 minus the ratio of slope C to slope A,
expressed as a percentage, for each sample (n¼ 16).
Before being extracted (reconstitution approach B or
C), the samples were volumetrically spiked to a final
concentration of 2.07 mM MTX, and the slopes of the
internal calibration curves were compared with the peak
area of the spiked unlabeled MTX to evaluate the rela-
tive matrix effects on MTX vs the internal calibrators.
PRECISION
The high- and low-pooled samples sourced at each site
were used for the evaluation of precision measurement,
based on CLSI EP05-A3 guidelines. The respective high
and low concentrations for each site were as follows:
0.404 and 4.3 mM at Site 1, 0.032 and 10.7 mM for Site
2, and 0.052 and 8.2 mM for Site 3. To estimate long-
term assay variability, Site 1 analyzed the same pooled
samples in duplicate on each of 20 days. All sites con-
ducted a 5-day, multisite precision study with 5 repli-
cates per patient pool for each of the 5 days. Intra- and
interday variability for both precision studies was calcu-
lated using ANOVA. Total variability was estimated by
the sum of squares method using Eq. 1:
Total Assay Variability ð%Þ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðCVwithin dayÞ2þðCVbetween dayÞ2
q
(1)
LOWER LIMIT OF QUANTIFICATION
The standard solution of MTX was serially diluted into
defibrinated plasma to generate samples with the follow-
ing target concentrations: 0.008, 0.016, 0.024, 0.032,
and 0.040 mM. Each dilution was measured in 5 repli-
cates on a single day. Intraday variability was deter-
mined as the percent CV of the 5 replicates, and the
precision and deviation from target concentrations of
these measurements were used to determine the lower
limit of quantification (LLOQ; <20%CV, within 20%
of target).
LINEARITY
The linear range of the assay was evaluated by perform-
ing a 2-sample mixing experiment that spanned the ana-
lytical measurable range (AMR), in accordance with
CLSI EP06-A2 guidelines. High- and low-pooled sam-
ples, which were sourced by each of the 3 locations, as
described, were mixed in 10% increments to generate a
total of 11 concentrations. Each concentration was pre-
pared and analyzed in triplicate.
METHOD COMPARISON
Forty patient samples or sample pools with MTX con-
centrations across the AMR were sent to all 3 sites for a
method comparison study, based on CLSI EP09-A3
guidelines. Site 1 compared MPIC with its in-house,
previously validated LC-MS/MS MTX clinical assay
(14), whereas Sites 2 and 3 compared the new method
with a commercial, 510(K)-cleared immunoassay
(ARK).
Modified Bland-Altman plots (17), or difference
(in percentage) plots, were used to assess agreement be-
tween 2 methods in the method comparison study. In
each case, the differences were calculated using Eq. 2:
Difference %ð Þ ¼ MPICMethod A
Method A
 100% (2)
Method A was either LC-MS/MS or ARK immu-
noassay, as appropriate. Results collected from these
Calibrating fromWithin
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samples were also used to evaluate reproducibility of
MPIC MTX quantification across 3 sites. To assess
interlaboratory variability, the percent CV of 1 measure-
ment per sample at each site was calculated. MTX se-
rum concentrations measured by Site 1’s LC-MS/MS
method were compared with the mean MPIC MTX
concentration from all 3 sites and the mean immunoas-
say MTX concentration at Sites 2 and 3.
DATA ANALYSIS
Results were processed using TargetLynx (Waters Corp)
and a Microsoft Excel macro. The MPIC macro deter-
mined the concentration of unlabeled MTX in each
sample using peak areas from the coeluting isotopically
labeled MTX ions and linear regression with 1/x weight-
ing and did not include the origin. For this analysis, the
regression line r2 was always >0.995 (not including the
unlabeled transition). Calibrators with residual bias ex-
ceeding 20% were either removed or the sample was re-
extracted. Other data analysis and figure generation
were performed in Excel and with the ggplot2 (18) and
other tidyverse (19) packages in R Studio (20).
Results
MPIC OF MTX
The stable isotope-labeled internal calibrators are chemi-
cally identical to the unlabeled MTX but with between
5 and 14 [13C] atoms incorporated (see Supplemental
Fig. 1). 13C was selected instead of deuterium to avoid
retention time shifts. Calibrators were carefully designed
to mitigate any isotopic contribution to or from any
other calibrator or unlabeled MTX. The target concen-
trations for the internal calibrators were 0.025, 0.1, 1.0,
and 10.0 mM, and a certified reference material was used
to determine the exact concentrations for data analysis:
0.026, 0.0967, 1.01, and 10.3 mM (Fig. 1). Calibrator
value assignment is described in detail in the online
Data Supplement. Each internal calibrator transition
consists of a unique parent and product ion pair.
Unlabeled MTX and all calibrators coelute at 0.79min
(Fig. 1, A), with unique parent m/z corresponding to
each internal calibrator transition observed (Fig. 1, B).
The coefficient of determination for the calibration lines
in all samples analyzed exceeded 0.999 (Fig. 1, C).
MULTISITE VALIDATION OF MPIC
Validation experiments performed by each site are sum-
marized in online Supplemental Table 4. Using MPIC,
recovery of MTX gravimetrically spiked into normal
matrix was 93.3%–102.0% (see Supplemental Table 5).
The impact of common interferences was evaluated in
samples with high concentrations of hemoglobin, trigly-
cerides, and total protein. Quantification of MTX
spiked into all common interference samples (n¼ 7)
was within 93.4%–117.0% of expected values (see
Fig. 1. Representative data from Site 2. (A) MTX and calibrators elute at 0.79min. Peak areas are normalized to 100%. (B) The
mass spectrum shows the unique parent m/z of the 4 internal calibrator transitions and MTX. (C) The calibration curve generated
from the integrated peak areas is used to quantify MTX. Of note, the origin is not included in the regression, and the unlabeled
transition is not included in the calculation of r2. The inset plot is zoomed in to the shaded region near the origin of the plot.
Cal, calibrator.
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Supplemental Table 6). Matrix effects were evaluated,
and mean 6 SD ion suppression of 42.36 11.1% and
mean 6 SD extraction efficiency of 78.36 22.1% were
observed (see Supplemental Table 7). The slopes of the
calibration curves in 16 different samples were strongly
correlated to the observed peak area of the spiked MTX,
suggesting that matrix effects affect the internal calibra-
tors and the unlabeled MTX similarly (see
Supplemental Fig. 5). Site 1 also determined the LLOQ
by evaluating intraday imprecision of 5 low-concentra-
tion samples ranging from 0.008 to 0.04 mM and apply-
ing 20%CV and 620% bias cutoffs (see Supplemental
Fig. 6). The LLOQ for quantifying MTX in serum with
MPIC was validated at 0.017mM.
The full 20-day precision study demonstrated
mean inter- and intraday imprecision of 8.9%CV and
7.3%CV (see Supplemental Tables 8–10). Total assay
variability, determined by ANOVA, was 11.9%CV and
11.1%CV at low and high concentrations, respectively.
The shortened, multisite, 5-day precision study esti-
mated assay variability similar to the 20-day, single-site
study and is summarized in Table 1. Total imprecision
(calculated using Eq. 1) was 10.8%, 5.95%, and 16.8%
at low concentrations and 14.3%, 3.36%, and 8.98% at
high concentrations at Sites 1, 2, and 3, respectively.
All 3 sites validated linearity across the calibrator
range (0.026–10.3 mM) with all r2 > 0.995 and slopes
between 0.996 and 1.01 (Fig. 2). The observed biases
for each concentration at all sites (n¼ 33) ranged from
6.3% to 8.2%.
INTERLABORATORY REPRODUCIBILITY
Forty samples with MTX concentrations spanning the
linear range of the assay were quantified by 2 methods
at each of the 3 sites. Results from MPIC analysis at
each of the 3 sites were used to assess inter-laboratory re-
producibility. Across all sites and samples, MPIC quan-
tification resulted in median imprecision of 6.55%CV
(interquartile rage: 3.9–13.2%CV, Fig. 3). Three of the
6 samples with variability exceeding 20% had MTX
concentrations < 0.04 mM, which is below most clini-
cally used cutoffs (Supplemental Table 11). One of the
3 sites had values that differed substantially from the
other 2 for these 6 samples.
COMPARISON OF MPIC AND TRADITIONAL LC-MS/MS
MPIC compared favorably with traditional LC-MS/MS
(14), with r2¼ 0.98 and slope¼ 1.04 (see Supplemental
Figs. 7 and 8, A). The differences plot shows a mean
bias of 5.3% when comparing the mean MPIC quan-
tification across the 3 sites to the LC-MS/MS compara-
tor method (Fig. 4, A). All but 2 values were within
620%, and those were both <0.04 mM.
COMPARISON OF IMMUNOASSAY AND TRADITIONAL
LC-MS/MS
The mean immunoassay MTX concentrations from
Sites 2 and 3 were compared with the LC-MS/MS com-
parator method (Site 1). A mean difference of 5.7% was
achieved between the 2 methods (Fig. 4, B), and all val-
ues except 1 exceeding 20% bias were <0.1 mM.
COMPARISON OF MPIC AND IMMUNOASSAY
MPIC also compared favorably with the ARK immuno-
assay with r2 values of 0.96–0.98 and slopes of 1.04–
1.06 (see Supplemental Fig. 8, B and C). Differences
between the immunoassay and MPIC rarely exceeded
620% for samples with MTX concentrations >1mM
(Fig. 5). Greater biases were observed at low MTX con-
centrations, as expected (21, 22).
Discussion
In this article, we describe a new calibration approach
suitable for mass spectrometry, MPIC, which demon-
strated excellent analytical performance in a multisite
study on 3 different LC-MS instruments following
CLSI guidelines. This approach was applied to MTX
analysis in serum as proof-of-concept. MPIC quantifica-
tion of MTX in serum showed good recovery in spiking
experiments; had no interference from high protein,
lipid, and hemoglobin concentrations; and was linear
throughout the calibrator range. The 5-day, multisite
and full 20-day, single-site precision studies both dem-
onstrated within- and between-day imprecision of 2.3–
14.1%CV and total variability of <17%CV. MTX
quantification in serum by MPIC showed low between-
laboratory variability and had strong correlations with a
previously validated LC-MS/MS method (14) and a
commercially available immunoassay.
MPIC offers the advantage of matrix-matched cali-
bration with every sample. This reduces the need for ex-
tensive matrix-effects studies (16) because external
calibrators are not spiked into a separate matrix. In
Table 1. Imprecision of the MPIC method at 3 sites.
CV (%)
Site 1 Site 2 Site 3
Low High Low High Low High
Interday 7.79 12.6 3.79 2.27 14.1 7.85
Intraday 7.45 6.81 4.59 2.47 9.15 4.35
Totala 10.8 14.3 5.95 3.36 16.8 8.98
Imprecision was evaluated by analyzing 5 replicates of a low and high QC mate-
rial on each of 5 days at each of the 3 participating laboratories.
aThe total variability was calculated using Eq. 1.
Calibrating fromWithin
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addition, the calibrators were designed with 13C to
avoid retention time shifts so that the internal calibra-
tors are subjected to the same ion suppression or en-
hancement effects as the analyte (23).
Increased biases and variability were observed at the
low end of MTX concentrations (<0.1 mM). Multiple
reasons are possible. First, the contradictory biases ob-
served between MPIC and the immunoassay run at
Sites 2 and 3 (mean bias, 11.4% and þ8.3%, respec-
tively) are most likely the result of variable calibration
across the 2 sites, which was particularly problematic at
low concentrations and consistent with previous studies
(24). Second, there could be variability in pipetting in
the MPIC assay, which would be improved with auto-
mated liquid handling. Third, the number of transitions
monitored at the same time point in the chromato-
graphic program is higher with internal calibration and
limits the number of points across the chromatographic
peak, which could lead to higher imprecision. Finally,
there could be matrix effects that affect the unlabeled
MTX differently than the internal calibrators; although
more extensive evaluation is warranted, our data seem to
suggest otherwise (see Supplemental Fig. 5).
Importantly, 6 specimens were highly variable be-
tween laboratories by the MPIC approach. In a post hoc
analysis, we examined the variability of the slopes of the
internal calibration curves and noticed that a cutoff of
30% below the mean slope for the day would have led
to 3 of the 6 samples being repeated at Site 3. This QC
approach would complement the stringent criteria for r2
(>0.995) and for the residuals of calibrators from the re-
gression line (<20%) that were used in this proof-of-
concept study. Although the residual of the calibrators
may provide an alternative to qualifier ion ratios for the
internal calibrators, it seems that including qualifier ion
ratios for the endogenous MTX would be prudent in fu-
ture configurations of this assay. Additional quality
Fig. 2. MPIC linearity. Two pooled samples with either a high or low concentration of MTX were mixed in 10% increments, gen-
erating 11-point curves. Each point represents the mean 6 SD (n¼ 3). The dashed line represents the linear regression line;
the corresponding equation and r2 are at the bottom of each panel.
Fig. 3. Interlaboratory reproducibility. Serum samples
(n¼ 40) were split and analyzed once at each site. The
mean MTX concentration is plotted against percent CV. The
dashed line is at 20%.
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assurance would include an MTX-free sample to evalu-
ate carryover daily.
The biases observed need to be examined from the
perspective of patient management. The plasma concen-
tration of MTX is commonly used in 2 ways. First, the
observed half-life is used to identify individuals for
whom pharmacological rescue will be required. Second,
the absolute concentration is used to clear patients to be
discharged from the hospital. In the first instance, con-
centrations above the upper limit of quantification of
the immunoassay are common, and although time-con-
suming dilutions are required for patient care, there
does not appear to be significant bias. In the second in-
stance, accuracy around the medical decision limit
(varies by center from 0.01 to 0.05 mM) is required, and
thus adequate QC is required for a novel MPIC assay.
Fortunately, more data elements are included in a mass
spectrometric result (in this case, including an entire cal-
ibration curve) than in an immunoassay, and this will
help ensure accurate results.
We have shown >2-fold improvement using
MPIC on the LLOQ compared with immunoassay
(0.017 vs 0.040 mM), based on the limit of quantifica-
tion defined in the ARK MTX assay package insert
Fig. 4. Method comparison to traditional LC-MS/MS. Serum samples were split and analyzed by MPIC at all 3 sites. (A)
Differences plot of mean MPIC value (all sites) vs the LC-MS/MS comparator method. (B) Differences plot of mean immunoassay
value (Sites 2 and 3) vs LC-MS/MS comparator method. The thin dashed lines are at620%, and the thick dashed lines are at the
mean biases.
Fig. 5. Comparison to an immunoassay. Serum samples were split and MTX analyzed by both immunoassay and MPIC at Sites 2
and 3 (same samples as in Fig. 4). The differences between methods were calculated using Eq. 2. Dashed lines are at 6 20%.
The y-axis is shared between the 2 plots.
Calibrating fromWithin
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(25). In addition, the immunoassay has an upper limit
of quantification of 1.2 mM, which is an order of magni-
tude lower than the highest calibrator used for MPIC
(10.3 mM). As mentioned briefly, in routine clinical
analysis, samples exceeding the upper limit of quantifi-
cation are serially diluted until the result is within the
AMR. Dilution is not automatable on many platforms;
therefore, it takes additional time and labor to repeat-
edly analyze samples until they are within range. More
than half of the patient samples required 1 dilution and
several required multiple dilutions to obtain immunoas-
say results in the reportable range in this study. MPIC
could help improve TAT by reducing the need for dilu-
tions in the vast majority of samples.
Currently, batch-mode testing performed by LC-
MS/MS in the clinical laboratory results in 12-h or lon-
ger TATs for most assays. Increased TATs are a major
limitation of LC-MS/MS (26). Longer TATs lead to
delayed patient treatment to prevent MTX toxicity,
resulting in worse clinical outcomes and prolong hospi-
tal length of stay. MPIC quantification is capable of re-
ducing TAT by allowing samples to be analyzed as they
arrive, enabling random-access clinical LC-MS/MS.
With the synthesis of the relevant isotopologues, MPIC
quantification should be applicable to other compounds
that require quick TATs (e.g., immunosuppressants). In
addition, laboratory efficiency is improved by reducing
resources required to prepare and analyze calibrators
with every batch of samples (27).
Conclusion
In a multisite study, we developed and validated an al-
ternative calibration strategy for clinical LC-MS/MS
assays that uses multiple internal calibrators. For proof-
of-concept, the chemotherapeutic drug MTX was used.
MPIC analysis correlated well with both immunoassay
and LC-MS/MS using a traditional calibration scheme.
Excellent reproducibility and linearity across 3 sites,
each with a different LC-MS/MS system, demonstrates
assay robustness. Elimination of external calibration
runs requiring sample batching can significantly reduce
TATs and improve the economic feasibility of
translating therapeutic drug-monitoring assays from im-
munoassay to an LC-MS/MS platform.
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